What is the number needed to vaccinate (NNV) to prevent one influenza‑related hospitalization in this age group, given 200 hospitalizations per 1,000 vaccinated individuals this year versus 60 per 1,000 vaccinated individuals last year?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 18, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Number Needed to Vaccinate (NNV) Calculation

Based on the data provided, the number needed to vaccinate (NNV) to prevent one hospitalization is 7. This is calculated using the absolute risk reduction formula: NNV = 1 ÷ (ARR), where ARR = 200/1000 - 60/1000 = 0.14 or 14%.

Step-by-Step Calculation

  • Baseline hospitalization rate (unvaccinated or this year's cohort): 200 per 1,000 = 20% 1
  • Post-vaccination hospitalization rate (last year's cohort): 60 per 1,000 = 6% 1
  • Absolute risk reduction (ARR): 20% - 6% = 14% 1
  • NNV = 1 ÷ 0.14 = 7.14, rounded to 7 1

Critical Context and Interpretation

This calculated NNV of 7 is extraordinarily favorable and represents an unusually high vaccine effectiveness of 70% in preventing hospitalizations. 1 This level of performance is at the absolute upper limit of typical influenza vaccine effectiveness and warrants careful interpretation.

Comparison to Real-World Data

  • Among elderly adults ≥65 years living outside nursing homes, influenza vaccine is typically 30-70% effective in preventing hospitalization for pneumonia and influenza, with most estimates clustering toward the lower end of this range 2
  • Among nursing home residents, vaccine effectiveness is 50-60% for preventing hospitalization or pneumonia 2
  • Recent real-world data from Quebec (2012-2019) showed NNV of 1,995 for adults ≥75 years with comorbidities—the highest-risk group comprising 39% of all hospitalizations 3
  • For healthy adults aged 18-64 years, the NNV was 163,488 to prevent one hospitalization 3

Important Caveats

The 14% absolute risk reduction demonstrated in your scenario is considerably higher than typical influenza vaccine performance, suggesting either optimal vaccine-strain matching, a particularly severe influenza season, or a selected high-risk population 1. Several critical factors affect this calculation:

  • Vaccine-strain matching: When circulating strains match vaccine strains well, effectiveness increases substantially; mismatched years show dramatically reduced effectiveness 2
  • Population risk stratification: Hospitalization rates vary 82-fold between highest-risk elderly with comorbidities (214 per 100,000) versus healthy younger adults (30 per 100,000) 3
  • Influenza subtype: A(H3N2) seasons produce higher hospitalization rates (73-143 per 100,000) compared to A(H1N1) seasons (49-82 per 100,000) 3

Transmission Effects Not Captured

Traditional NNV calculations that ignore indirect transmission effects can overestimate the true NNV by up to 1,000-fold, meaning the actual number needed to vaccinate may be even lower when accounting for herd immunity and reduced community transmission 4. This is particularly relevant for influenza, which has substantial person-to-person transmission.

Mortality and Quality of Life Considerations

Beyond hospitalization prevention, influenza vaccination provides critical mortality benefits:

  • Among nursing home residents, vaccine is 80% effective in preventing death, even when effectiveness against illness itself is only 30-40% 2, 1
  • More than 90% of influenza deaths occur in adults ≥65 years, with 20,000-40,000 deaths during severe epidemic years 2, 1
  • The estimated rate of influenza-associated death ranges from 300 to >1,500 per million persons aged ≥65 years 1

Pediatric Comparisons

For context in other age groups:

  • Among children 6-23 months with 50% vaccine efficacy, NNV ranges from 1,031 to 3,050 to prevent one hospitalization 5
  • Among children 24-59 months with 50% vaccine efficacy, NNV ranges from 4,255 to 6,897 to prevent one hospitalization 5
  • For outpatient visits, only 12-42 children aged 6-59 months need vaccination to prevent one influenza-attributable visit 5

References

Guideline

Influenza Hospitalization Prevention Guideline

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Influenza Hospitalization Burden by Subtype, Age, Comorbidity, and Vaccination Status: 2012-2013 to 2018-2019 Seasons, Quebec, Canada.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024

Related Questions

What is the number needed to vaccinate to prevent one hospitalization due to influenza in individuals aged 50 or older, given a hospitalization rate of 20% in unvaccinated and 6% in vaccinated individuals?
What is the number needed to vaccinate (NNV) to prevent one hospitalization?
What is the number needed to vaccinate to prevent one hospitalization due to influenza in individuals over 50 years old?
What is the number needed to vaccinate to prevent one hospitalization due to influenza in individuals greater than 50 years of age?
What is the number needed to vaccinate (NNV) to prevent one hospitalization in individuals over 50 years of age who contract influenza?
Should a patient with active disseminated herpes zoster receive the shingles vaccine, and if so, when and which formulation is appropriate?
What is the drug of choice for uncomplicated typhoid fever in adults?
How should I evaluate and manage a patient with sinus bradycardia and borderline first-degree atrioventricular (AV) block?
I've been taking Vyvanse (lisdexamfetamine) for ADHD and now have increased fidgeting and lip‑biting; are these side effects and how should I manage them?
In a 30‑year‑old adult presenting with intermittent right‑lower‑quadrant abdominal pain, crampy diarrhea, occasional blood or mucus in stool, weight loss, low‑grade fever, mild anemia, elevated C‑reactive protein and hypoalbuminemia, colonoscopy shows patchy inflammation of the terminal ileum; what are the likely etiologies, recommended diagnostic work‑up, and appropriate management?
What imaging, assessment, and treatment are recommended for a symptomatic 38‑year‑old woman with a known umbilical hernia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.